Global Cord Blood (NYSE:CORBF) vs. Progyny (NASDAQ:PGNY) Head to Head Review

Global Cord Blood (NYSE:CORBF) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Global Cord Blood and Progyny, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0	0	0	0	N/A
Progyny	0	0	10	0	3.00

Progyny has a consensus price target of $48.11, suggesting a potential upside of 48.03%. Given Progyny’s higher probable upside, analysts plainly believe Progyny is more favorable than Global Cord Blood.

Profitability

This table compares Global Cord Blood and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Progyny	5.70%	12.64%	8.82%

Valuation & Earnings

This table compares Global Cord Blood and Progyny’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$196.12 million	0.76	$79.04 million	N/A	N/A
Progyny	$1.09 billion	2.87	$62.04 million	$0.62	52.42

Global Cord Blood has higher earnings, but lower revenue than Progyny.

Volatility & Risk

Global Cord Blood has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Insider and Institutional Ownership

94.9% of Progyny shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by company insiders. Comparatively, 12.3% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Progyny beats Global Cord Blood on 10 of the 11 factors compared between the two stocks.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.